Literature DB >> 8865249

Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure.

B Hoppe1, D Graf, G Offner, K Latta, D J Byrd, D Michalk, J Brodehl.   

Abstract

Oxalate elimination and oxalate dialysance via hemodialysis (HD) or peritoneal dialysis (CAPD) has not been studied in detail in pediatric patients. We studied plasma oxalate, oxalate elimination, and oxalate dialysance in 15 infants and children undergoing CAPD (9 female, 6 male, aged 9 months to 18 years) and in 10 children on HD (4 female, 6 male, aged 7-18 years). Two children in each group had primary hyperoxaluria (PH). The mean duration of dialysis prior to examination was 12 +/- 11 months in CAPD and 31 +/- 23 months in HD patients. Bicarbonate HD was performed 5 h three times a week, CAPD consisted of five daily exchanges in 5 patients and four changes in the remaining 10 children (dwell volume 40 ml/kg body weight, 2.3 g/l glucose). Although oxalate dialysance was significantly higher in HD (mean 115.6 ml/ min per 1.73 m2 in HD versus 7.14 ml/min in CAPD), mean oxalate elimination per week was not different between both renal replacement therapies (3,478 mumol/1.73 m2 surface area/week in CAPD versus 3,915 mumol/1.73 m2 per week in HD). Oxalate elimination in patients with PH was between 6,650 and 9,900 mumol/week. Plasma oxalate remained elevated in both procedures [28-84 mumol/l in CAPD (92/148 in PH) and 33-101 mumol/l in HD (70/93 in PH)]. Oxalate elimination can be increased by a more frequent hemodialysis regimen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8865249     DOI: 10.1007/s004670050145

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

1.  Primary hyperoxaluria type 1 with a novel mutation.

Authors:  Sidharth Kumar Sethi; Hans R Waterham; Sonika Sharma; Alok Sharma; Pankaj Hari; Arvind Bagga
Journal:  Indian J Pediatr       Date:  2008-09-22       Impact factor: 1.967

2.  Hyperoxaluria and rapid development of renal failure following a combined liver and kidney transplantation: emphasis on sequential transplantation.

Authors:  Ahmed M Alkhunaizi; Nouriya A Al-Sannaa; Wasim F Raslan
Journal:  JIMD Rep       Date:  2011-09-06

Review 3.  Primary hyperoxalurias: diagnosis and treatment.

Authors:  Efrat Ben-Shalom; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2014-12-18       Impact factor: 3.714

4.  A non-resolving skin lesion in hemodialysis patient: Answers.

Authors:  Shimrit Tzvi-Behr; Efrat Ben-Shalom; Rachel Becker-Cohen; Graciela Lijozetzky; Jenny Weinbrand-Goichberg; Yaacov Frishberg; Choni Rinat
Journal:  Pediatr Nephrol       Date:  2018-08-28       Impact factor: 3.714

Review 5.  Primary and secondary hyperoxaluria: Understanding the enigma.

Authors:  Bhavna Bhasin; Hatice Melda Ürekli; Mohamed G Atta
Journal:  World J Nephrol       Date:  2015-05-06

Review 6.  An update on primary hyperoxaluria.

Authors:  Bernd Hoppe
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

7.  Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies.

Authors:  Bodo B Beck; Anne Baasner; Anja Buescher; Sandra Habbig; Nadine Reintjes; Markus J Kemper; Przemyslaw Sikora; Christoph Mache; Martin Pohl; Mirjam Stahl; Burkhard Toenshoff; Lars Pape; Henry Fehrenbach; Dorrit E Jacob; Bernd Grohe; Matthias T Wolf; Gudrun Nürnberg; Gökhan Yigit; Eduardo C Salido; Bernd Hoppe
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

Review 8.  The primary hyperoxalurias.

Authors:  Bernd Hoppe; Bodo B Beck; Dawn S Milliner
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

9.  A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria.

Authors:  Bernd Hoppe; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2003-08-15       Impact factor: 3.714

Review 10.  Update on oxalate crystal disease.

Authors:  Elizabeth C Lorenz; Clement J Michet; Dawn S Milliner; John C Lieske
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.